Deciphering the Colorectal Tumor Microenvironment: Interactions and Targets for Effective Therapy
22 Articles
22 Articles
Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China
SAN FRANCISCO and SUZHOU, China, Aug. 5, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major…
Deciphering the Colorectal Tumor Microenvironment: Interactions and Targets for Effective Therapy
The authors highlight how interactions within the colorectal tumor microenvironment drive metastasis, immune evasion, and therapy resistance, revealing new opportunities for combination cancer therapies. [Biochemical Pharmacology] AbstractGraphical Abstract
Coverage Details
Bias Distribution
- 90% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium







